Clinical Trials
38 trialsNCT07005128 2026-06-04
DeLLphi-312
Amgen
Phase 3 Recruiting
NCT07625644 2026-06-04
Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer
SystImmune Inc.
Phase 3 Not yet recruiting
NCT00379340 2026-06-03
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Children's Oncology Group
Phase 3 Completed
NCT02101853 2026-06-03
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02112916 2026-06-03
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02306161 2026-06-03
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05675410 2026-06-03
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06172296 2026-06-03
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT01371981 2026-06-02
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 3 Completed
NCT02883049 2026-06-02
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
National Cancer Institute (NCI)
Phase 3 Completed
NCT07472517 2026-06-02
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
Boehringer Ingelheim
Phase 3 Recruiting
NCT03811002 2026-06-01
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06646276 2026-06-01
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Bristol-Myers Squibb
Phase 3 Recruiting
NCT06712355 2026-06-01
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
BioNTech SE
Phase 3 Recruiting
NCT04092283 2026-05-29
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02003222 2026-05-28
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT01993810 2026-05-27
Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT07544654 2026-05-27
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Boehringer Ingelheim
Phase 3 Not yet recruiting
NCT04624204 2026-05-26
MK 7339-013
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT00734877 2026-05-22
TT4B
University of Arkansas
Phase 3 Active not recruiting
NCT06564844 2026-05-22
TROPION-Lung12
AstraZeneca
Phase 3 Active not recruiting
NCT04380636 2026-05-15
MK-7339-012
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03017326 2026-05-13
PHITT
University of Birmingham
Phase 3 Active not recruiting
NCT06230224 2026-05-11
OLYMPIA-4
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT02176967 2026-05-05
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
Children's Oncology Group
Phase 3 Active not recruiting
NCT03067181 2026-05-05
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Children's Oncology Group
Phase 3 Recruiting
NCT03182244 2026-05-05
A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT04293562 2026-05-05
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Children's Oncology Group
Phase 3 Recruiting
NCT06401330 2026-05-05
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Children's Oncology Group
Phase 3 Recruiting
NCT03007147 2026-05-04
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 3 Active not recruiting
NCT05624996 2026-05-04
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NRG Oncology
Phase 3 Recruiting
NCT01096368 2026-04-30
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
Children's Oncology Group
Phase 3 Completed
NCT02633514 2026-04-27
Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma
Fudan University
Phase 3 Withdrawn
NCT03043872 2026-04-22
CASPIAN
AstraZeneca
Phase 3 Active not recruiting
NCT07502300 2026-04-20
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT03583710 2026-04-07
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
M.D. Anderson Cancer Center
Phase 3 Recruiting
NCT04256421 2026-04-03
SKYSCRAPER-02
Hoffmann-La Roche
Phase 3 Completed
NCT02845882 2026-03-18
LBL-2016 for Children or Adolescents in China
Children's Cancer Group, China
Phase 3 Active not recruiting